| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2008;39:2046.)
© 2008 American Heart Association, Inc.
Original Contributions |
From the Department of Neurology, EA 2691, Memory Center (S.B., S.D., X.D., F.P.) and Stroke unit (S.D., D.L.), and the Department of Neuroradiology (C.D.), Lille University Hospital; and Inserm Unit U744, Pasteur Institute of Lille (A.B.), France.
Correspondence to Pr Pasquier, Department of Neurology, University Hospital 59037 Lille, France. E-mail pasquier{at}chru-lille.fr
| Abstract |
|---|
|
|
|---|
Methods— This was an observational study on consecutive MCI patients attending a memory clinic. We assessed SH on a baseline MRI scan, using a semiquantitative rating scale. A multivariable Cox regression model was used to test the association of SH with conversion to dementia.
Results— We included 170 MCI patients. The median duration of follow-up was 3.8 years. During this period, 67 patients (39.4%, 95% CI: 32.1 to 46.8%) developed dementia: Alzheimer disease (AD) in 29 patients, dementia with Lewy bodies in 19, mixed dementia in 8, vascular dementia in 7, fronto-temporal dementia in 2, and primary progressive aphasia in 2. SH were not associated with the risk to develop dementia as a whole, including AD. However, the risk to develop vascular or mixed dementia increased significantly with increasing amounts of SH at baseline (HR=1.14 [95% CI: 1.06 to 1.24]), especially periventricular hyperintensities (HR=2.71 [95% CI: 1.60 to 4.58]), independently of medial temporal lobe atrophy, age, gender, vascular risk factors, education, and cognitive functions at baseline.
Conclusion— The risk of vascular or mixed dementia, but not of other types of dementia, was significantly increased in MCI patients with a large amount of subcortical hyperintensities at baseline.
Key Words: mild cognitive impairment subcortical vascular lesions conversion vascular dementia Alzheimer disease
| Introduction |
|---|
|
|
|---|
4 allele6,7 were found to predict conversion to dementia. There is much less data on predictors of conversion to dementia in nonamnestic MCI, and on conversion of MCI patients to non-AD dementia. Although population-based studies have suggested that silent brain infarcts and cerebral white matter lesions increase the risk of dementia in elderly people,10–12 the question of whether subcortical hyperintensities predict conversion to dementia in MCI patients is still unresolved. Two studies have investigated the association of subcortical lesions with conversion to dementia in MCI patients,13,14 providing conflicting results. In a previous paper, we have shown that the annual rate of global cognitive decline in MCI patients was higher with increasing amounts of subcortical, and especially periventricular hyperintensities on cerebral MRI at baseline, irrespective of the MCI subtype.15 The aim of the present study was to test the hypothesis that subcortical hyperintensities are associated with an increased rate of conversion to dementia in MCI patients.
| Methods |
|---|
|
|
|---|
We prospectively collected demographic characteristics, vascular risk factors, and history of vascular disease using a standardized questionnaire.15 Arterial hypertension was defined as a blood pressure value >140/90 mm Hg (or >130/80 mm Hg in diabetics) at rest on 2 separate measurements, or a current antihypertensive therapy; diabetes mellitus as a fasting blood glucose level >7.00 mmol/L on 2 separate occasions, or a current antidiabetic therapy; hypercholesterolemia as a total cholesterol level >5.93 mmol/L, or a current cholesterol lowering therapy. We excluded patients with history of stroke or transient ischemic attack or silent territorial cortical infarcts, but not those with silent subcortical infarcts.
Global cognition was assessed with the Mini Mental State Examination (MMSE)16 and the Mattis Dementia Rating Scale (DRS).17 Memory, attention, executive functions, visuospatial abilities, language, and praxis were evaluated in all patients using a neuropsychological battery detailed in previous publications.15,18
All patients had an MRI scan at baseline on a 1.5 Tesla machine (T2-weighted, spin-echo, and fluid attenuation inversion recovery [FLAIR] sequences, TE: 20 and 60 ms, TR: 2500 ms, section thickness: 5.0 mm). Subcortical hyperintensities (SH) were assessed on FLAIR imaging by an investigator blinded to the cognitive status of the patients (S.B.), using a previously validated semiquantitative rating scale.19 T2-weighted imaging was used to validate or not hypointensities on Flair sequences as vascular lesions. In addition to the total amount of subcortical hyperintensities (SH, range: 0 to 84), 4 subtypes of subcortical hyperintensities were assessed: periventricular hyperintensities (PVH, range: 0 to 6), white matter hyperintensities (WMH, range: 0 to 24), hyperintensities in the basal ganglia (BG, range: 0 to 30), and infratentorial hyperintensities (ITF, range: 0 to 24). The intrarater weighted kappa for SH, determined on 31 MRI-scans, was good (
=0.62 [95% CI: 0.48 to 077]), as previously reported.19 This scale was shown to correlate well with volumetric measurements.20 We also assessed medial temporal lobe atrophy, using another previously validated semiquantitative rating scale.21 Medial temporal lobe atrophy was previously shown to be associated with conversion to dementia in MCI patients9 and is also associated with white matter lesions.22,23 It is therefore a potential confounder that should be adjusted for when evaluating the relationship between subcortical hyperintensities and conversion to dementia.
We followed-up all patients at least once a year. At each visit, we repeated the same standardized neurological and neuropsychological evaluation and evaluated the autonomy in activities of daily living.24 Additional structural brain imaging and functional brain imaging (SPECT) were performed when clinically indicated. We collected information on incident strokes and transient ischemic attacks. We diagnosed dementia using: (1) the National Institute of Neurological and Communication Disorders-Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA) criteria25 for probable or possible AD, (2) the McKeith criteria26 for probable or possible DLB, (3) the Lund and Manchester criteria for frontotemporal dementia,27 (4) the Mesulam criteria28 for primary progressive aphasia, (5) the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et lEnseignement en Neurosciences (NINDS-AIREN) criteria29 for VD. Because we excluded patients with a history of stroke, the disease onset was subtle and the course of the cognitive decline variable. Therefore, according to the NINDS-AIREN criteria, only possible VD could be diagnosed. There are no international diagnostic criteria for the diagnosis of mixed dementia (MD). However, in the NINDS-AIREN criteria,29 the term AD with cerebrovascular disease (CVD) is reserved to patterns fulfilling the clinical criteria of possible AD who have also clinical and imaging signs of relevant CVD. In the present study, we diagnosed mixed dementia in patients with an AD-type cognitive profile in addition to a prominent executive dysfunction on neuropsychological assessment, and with either hyperintensities in a strategic area known to be associated with cognition (such as the thalamus) or multiple subcortical hyperintensities in the white matter on cerebral MRI. The final diagnosis was reviewed by a multidisciplinary board including neurologists, psychiatrists, neuropsychologists, and speech therapists.
Statistical analyses were performed with the SAS 8.02 software package (SAS Institute Inc). All tests were 2-tailed, a probability value of <0.05 being considered as statistically significant. The bivariate comparisons between groups were performed with the Chi-square test for qualitative variables and the Kruskal-Wallis test for continuous variables. We studied subcortical hyperintensities firstly as a continuous and secondly as a binary variable (the median of the distribution being used as a cut-off). We used a univariate and multivariable Cox regression model to test the association of subcortical hyperintensities with conversion to dementia. The multivariable model was adjusted for age, gender, educational level, vascular risk factors, medial temporal lobe atrophy, memory, and executive dysfunction at baseline, as well as baseline DRS score (as a marker of baseline global cognitive functions). The duration of follow-up corresponds to the time between the first and the last visit in the memory clinic for nonconverters and to the time between the first visit to the memory clinic and the estimated date of conversion to dementia for converters (data are right-censored at the date of conversion to dementia). For the statistical analyses vascular and mixed dementia were studied together because of small numbers.
| Results |
|---|
|
|
|---|
|
The mean value and the range of SH in each location in nonconverters and in converters within the main subtypes of dementia is depicted in Figure 1, showing larger mean values of SH at baseline in patients who subsequently developed VD and MD compared to patients who did not. The overlapping ranges of SH values in patients with different types of dementia reflect the fact that the diagnosis of VD or MD was not based on SH values alone, but on a whole set of arguments, including neuropsychological profile and cognitive history.
|
In an univariate Cox regression model, there was a weak borderline significant association of subcortical hyperintensities with an increased risk to develop any type of dementia (HR=1.03, 95% CI: 1.00 to 1.07). In a multivariable Cox regression model, executive dysfunction, lower DRS score, and temporal lobe atrophy at baseline, but not subcortical hyperintensities, significantly predicted conversion to dementia (Table 2). When studying the different types of dementia, increasing amounts of SH at baseline were significantly associated with an increased risk to develop vascular or mixed dementia (HR=1.14 [95% CI: 1.07 to 1.22], Table 3), but not other types of dementia (data not shown). After adjustment for age, gender, educational level, and temporal lobe atrophy the association between SH and conversion to vascular or mixed dementia was unchanged (HR=1.11 [95% CI: 1.04 to 1.20]). Similar results were found after adjusting additionally for vascular risk factors (HR=1.13 [95% CI: 1.05 to 1.22]), and cognitive functions at baseline (HR=1.14 [95% CI: 1.06 to 1.24]; Table 3). The results were also similar when excluding from the analysis subjects who developed another type of dementia (HR=1.11 [95% CI: 1.03 to 1.20]). Thus, SH were more diffuse at baseline in MCI patients who subsequently converted to VD or MD compared to MCI patients who did not convert to dementia. The association of SH with conversion to vascular or mixed dementia did not differ significantly according to the presence or absence of memory or executive dysfunction at baseline (P for interaction=0.09 and 0.78, respectively). When testing the association of the different subtypes of SH according to their location, using the same multivariable model, we found that both PVH (HR=2.71 [95% CI: 1.60 to 4.58]) and WMH (HR=1.16 [95% CI: 1.06 to 1.28]), but not BG or ITF, significantly predicted conversion to VD or MD. When studying conversion to VD and MD separately, a similar trend was found in both cases (HR=1.20 [95% CI: 0.97 to 1.48] for the association of SH with VD, and HR=1.24 [95% CI: 0.99 to 1.53] for the association of SH with MD).
|
|
When subcortical hyperintensities were studied as a binary variable, 2 of 84 patients with SH
6 (median of the distribution), and 13 of 86 patients with SH >6 developed vascular or mixed dementia. Compared to subjects with SH
6, the risk to develop vascular or mixed dementia was increased (HR=10.00 [95% CI: 1.55 to 64.39]) in subjects with SH >6, independently of medial temporal lobe atrophy, age, gender, vascular risk factors, education, memory, and executive dysfunction, and DRS score at baseline (Figure 2).
|
All these results remained unchanged after exclusion of the 15 patients who did not convert to dementia and had a follow-up of less than 2 years.
| Discussion |
|---|
|
|
|---|
Our study has some limitations. Although patients were followed-up for more than 3 years on average, it is probable that some patients classified as nonconverters would have developed dementia after a longer follow-up period. This, as well as insufficient statistical power, may have hampered our ability to detect an association of SH with dementia other than of vascular or mixed origin, especially AD. Although we have no pathological proof of the dementia type for most patients in this series, the accuracy of the clinical diagnosis of dementia in our center has been assessed in 100 consecutive patients who came to autopsy between 1993 and 2007, and was 80.0% for DLB (n=15), 93.3% for MD (n=15), 93.8% for AD (n=32), and 100% for VD (n=3) (Deramecourt V, personal communication, 2007). The fact that our memory clinic is a regional referral center, non-AD dementia probably accounts for the large proportion of DLB in the present study. As our study is retrospective and APOE
4 is not warranted for the diagnosis of dementia, this factor was not included in our analyses. However, even though APOE
4 has been suggested to predict conversion of amnestic MCI patients to Alzheimer disease, when cognitive performances are taken into account, predictive models with or without the APOE
4 status were shown to have a similar accuracy.30 Moreover, there are no data on the predictive value of APOE
4 on conversion to dementia in nonamnestic MCI. The lack of information on APOE
4 status in the present analyses is therefore unlikely to be a strong bias.
Compared to the few previous studies that assessed the impact of subcortical lesions on conversion to dementia in MCI patients,13,14 the study described herein was performed on a larger population and is the first to test the association of subcortical lesions with conversion to different types of dementia. One previous study13 found an association between white matter changes on CT-scan and conversion to AD in 27 MCI patients. Another study14 failed to demonstrate any association between vascular lesions on cerebral MRI and conversion to dementia in 52 MCI patients and found that the impairment in memory and executive performance were the best predictors of conversion. Compared to the first study where white matter changes were probably quite extensive to be visible on CT-scan,13 large volumes of white matter lesions were uncommon in the second study,14 reducing the power to detect an effect of these lesions. Furthermore, none of these studies assessed the relationship between subcortical lesions and conversion to different types of dementia. In line with DeCarli et al,14 we found no association between subcortical hyperintensities and conversion to any type of dementia, the best predictors being medial temporal lobe atrophy, baseline executive dysfunction, and DRS score. We did, however, demonstrate that a large amount of subcortical hyperintensities in the periventricular and deep white matter independently predicted subsequent conversion to vascular or mixed dementia. This association was not assessed by DeCarli et al.14 The outcome measure they used was the Clinical Dementia Rating Scale (CDR), which, as mentioned by the authors, emphasizes memory-related cognitive impairment common to AD, suggesting that most cases of dementia in this cohort actually were AD.14 The criteria used for the diagnosis of dementia in the present study were wider and included specific criteria for other types of dementia than AD,26,28,29 enabling us to detect an association between subcortical hyperintensities and vascular and mixed dementia. This could also explain why we found an association of executive but not memory dysfunction with conversion to dementia.
Our results suggest that, among MCI patients attending a memory clinic, subcortical vascular lesions independently predict the subsequent occurrence of vascular and mixed dementia, but do not significantly influence conversion to other types of dementia, such as AD or DLB. This association needs to be confirmed in other independent MCI populations. If it is replicated, only a therapeutic trial aiming to reduce the white matter lesion load could prove that the relationship is causal. In case of coexisting neuropathological AD lesions, it could be hypothesized that subcortical vascular lesions influence conversion to dementia only if their progression rate is faster than the progression rate of AD lesions. Lesion severity at baseline being the main predictor of SH progression,31,32 one would expect SH to influence conversion to dementia mainly in patients with large amounts of SH at baseline. In other cases, AD lesions probably overwhelm the effect of subcortical lesions and become the major determinant of dementia.33 In our cohort, patients with dementia fulfilling both criteria for AD25 and VD29 were classified as MD. Accordingly, patients diagnosed as "pure" AD were less likely to have extensive and rapidly evolving SH (see Figure 1) that may accelerate the shift from MCI to dementia. Future studies with repeated MRI scans are warranted to explore this hypothesis. Future studies assessing the independent effect of lacunes and WMH on progression of MCI patients to dementia could also be of interest. Recent publications have indeed suggested that these 2 types of subcortical lesions may be independently related to cognitive function in elderly community subjects,34 and that lacunes, but not WMH, could be associated with cognitive performance in MCI patients with milder medial temporal lobe atrophy.22
In conclusion, increasing amounts of periventricular and deep white matter hyperintensities at baseline predicted conversion to vascular and mixed dementia in MCI patients attending a memory clinic. Even though validation of our results in independent populations is required, they suggest that MCI patients with diffuse subcortical hyperintensities at the initial evaluation ought to be followed-up more closely, because they seem to be at higher risk of conversion to vascular or mixed dementia. Subcortical lesions should also be taken into account in therapeutic trials targeting MCI patients.
| Acknowledgments |
|---|
Disclosures
None.
| Footnotes |
|---|
Received September 21, 2007; revision received November 12, 2007; accepted November 21, 2007.
| References |
|---|
|
|
|---|
2. Tierney MC, Szalai JP, Snow WG, Fisher RH, Tsuda T, Chi H, McLachlan DR, St George-Hyslop PH. A prospective study of the clinical utility of apoE genotype in the prediction of outcome in patients with memory impairment. Neurology. 1996; 46: 149–154.
3. Palmer K, Wang HX, Backman L, Winblad B, Fratiglioni L. Differential evolution of cognitive impairment in nondemented older persons: Results from the kungsholmen project. Am J Psychiatry. 2002; 159: 436–442.
4. Devanand DP, Folz M, Gorlyn M, Moeller JR, Stern Y. Questionable dementia: Clinical course and predictors of outcome. J Am Geriatr Soc. 1997; 45: 321–328.[Medline] [Order article via Infotrieve]
5. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001; 58: 397–405.
6. Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, Kokmen E, Waring SC, Kurland LT. Apolipoprotein e status as a predictor of the development of Alzheimers disease in memory-impaired individuals. JAMA. 1995; 273: 1274–1278.
7. Tabert MH, Manly JJ, Liu X, Pelton GH, Rosenblum S, Jacobs M, Zamora D, Goodkind M, Bell K, Stern Y, Devanand DP. Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatry. 2006; 63: 916–924.
8. Saxton J, Lopez OL, Ratcliff G, Dulberg C, Fried LP, Carlson MC, Newman AB, Kuller L. Preclinical Alzheimer disease: Neuropsychological test performance 1.5 to 8 years prior to onset. Neurology. 2004; 63: 2341–2347.
9. Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, Rusinek H, Pelton GH, Honig LS, Mayeux R, Stern Y, Tabert MH, de Leon MJ. Hippocampal and entorhinal atrophy in mild cognitive impairment: Prediction of Alzheimer disease. Neurology. 2007; 68: 828–836.
10. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003; 348: 1215–1222.
11. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Cerebral white matter lesions and the risk of dementia. Arch Neurol. 2004; 61: 1531–1534.
12. Kuller LH, Lopez OL, Newman A, Beauchamp NJ, Burke G, Dulberg C, Fitzpatrick A, Fried L, Haan MN. Risk factors for dementia in the cardiovascular health cognition study. Neuroepidemiology. 2003; 22: 13–22.[CrossRef][Medline] [Order article via Infotrieve]
13. Wolf H, Ecke GM, Bettin S, Dietrich J, Gertz HJ. Do white matter changes contribute to the subsequent development of dementia in patients with mild cognitive impairment? A longitudinal study. Int J Geriatr Psychiatry. 2000; 15: 803–812.[CrossRef][Medline] [Order article via Infotrieve]
14. DeCarli C, Mungas D, Harvey D, Reed B, Weiner M, Chui H, Jagust W. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology. 2004; 63: 220–227.
15. Debette S, Bombois S, Bruandet A, Delbeuck X, Lepoittevin S, Delmaire C, Leys D, Pasquier F. Subcortical hyperintensities are associated with cognitive decline in patients with mild cognitive impairment. Stroke. 2007; 38: 2924–2930.
16. Folstein MF, Folstein SE, McHugh PR. "mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189–198.[CrossRef][Medline] [Order article via Infotrieve]
17. Mattis S. Dementia Rating Scale. Winsor: NFER-Nelson; 1973.
18. Bombois S, Debette S, Delbeuck X, Bruandet A, Lepoittevin S, Delmaire C, Leys D, Pasquier F. Prevalence of subcortical vascular lesions and association with executive function in mild cognitive impairment subtypes. Stroke. 2007; 38: 2595–2597.
19. Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJ, Vermersch P, Steinling M, Valk J. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci. 1993; 114: 7–12.[CrossRef][Medline] [Order article via Infotrieve]
20. Kapeller P, Barber R, Vermeulen RJ, Ader H, Scheltens P, Freidl W, Almkvist O, Moretti M, del Ser T, Vaghfeldt P, Enzinger C, Barkhof F, Inzitari D, Erkinjunti T, Schmidt R, Fazekas F. Visual rating of age-related white matter changes on magnetic resonance imaging: Scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke. 2003; 34: 441–445.
21. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J. Atrophy of medial temporal lobes on mri in "probable" Alzheimers disease and normal ageing: Diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992; 55: 967–972.
22. van de Pol LA, Korf ES, van der Flier WM, Brashear HR, Fox NC, Barkhof F, Scheltens P. Magnetic resonance imaging predictors of cognition in mild cognitive impairment. Arch Neurol. 2007; 64: 1023–1028.
23. Mungas D, Jagust WJ, Reed BR, Kramer JH, Weiner MW, Schuff N, Norman D, Mack WJ, Willis L, Chui HC. Mri predictors of cognition in subcortical ischemic vascular disease and Alzheimers disease. Neurology. 2001; 57: 2229–2235.
24. Johnson N, Barion A, Rademaker A, Rehkemper G, Weintraub S. The activities of daily living questionnaire: A validation study in patients with dementia. Alzheimer Dis Assoc Disord. 2004; 18: 223–230.[Medline] [Order article via Infotrieve]
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimers disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimers disease. Neurology. 1984; 34: 939–944.
26. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M. Diagnosis and management of dementia with lewy bodies: Third report of the dlb consortium. Neurology. 2005; 65: 1863–1872.
27. Clinical and neuropathological criteria for frontotemporal dementia. The lund and manchester groups. J Neurol Neurosurg Psychiatry. 1994; 57: 416–418.
28. Mesulam MM. Primary progressive aphasia. Ann Neurol. 2001; 49: 425–432.[CrossRef][Medline] [Order article via Infotrieve]
29. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology. 1993; 43: 250–260.
30. Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. 2007; 68: 1588–1595.
31. Sachdev P, Wen W, Chen X, Brodaty H. Progression of white matter hyperintensities in elderly individuals over 3 years. Neurology. 2007; 68: 214–222.
32. Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F. Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention study. Lancet. 2003; 361: 2046–2048.[CrossRef][Medline] [Order article via Infotrieve]
33. Chui HC, Zarow C, Mack WJ, Ellis WG, Zheng L, Jagust WJ, Mungas D, Reed BR, Kramer JH, Decarli CC, Weiner MW, Vinters HV. Cognitive impact of subcortical vascular and Alzheimers disease pathology. Ann Neurol. 2006; 60: 677–687.[CrossRef][Medline] [Order article via Infotrieve]
34. van der Flier WM, van Straaten EC, Barkhof F, Verdelho A, Madureira S, Pantoni L, Inzitari D, Erkinjuntti T, Crisby M, Waldemar G, Schmidt R, Fazekas F, Scheltens P. Small vessel disease and general cognitive function in nondisabled elderly: The LADIS study. Stroke. 2005; 36: 2116–2120.
This article has been cited by other articles:
![]() |
J. V. Bowler and P. B. Gorelick Advances in Vascular Cognitive Impairment Stroke, May 1, 2009; 40(5): e315 - e318. [Full Text] [PDF] |
||||
![]() |
S. S. Staekenborg, E. L.G.E. Koedam, W. J.P. Henneman, P. Stokman, F. Barkhof, P. Scheltens, and W. M. van der Flier Progression of Mild Cognitive Impairment to Dementia: Contribution of Cerebrovascular Disease Compared With Medial Temporal Lobe Atrophy Stroke, April 1, 2009; 40(4): 1269 - 1274. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |